Suppr超能文献

从过饱和喷雾干燥无定形固体分散体中测定药物-聚合物溶解度:以依非韦伦和Soluplus®为例。

Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus®.

机构信息

Université de Toulouse, Ecole des Mines d'Albi, UMR CNRS 5302, Centre RAPSODEE, F-81013 Albi, France.

Université de Toulouse, Ecole des Mines d'Albi, UMR CNRS 5302, Centre RAPSODEE, F-81013 Albi, France.

出版信息

Eur J Pharm Biopharm. 2019 Sep;142:300-306. doi: 10.1016/j.ejpb.2019.06.028. Epub 2019 Jun 24.

Abstract

Amorphous solid dispersions (ASDs) are found to be a well-established strategy for overcoming limited aqueous solubility and poor oral bioavailability of active pharmaceutical ingredients (APIs). One of the main parameters affecting ASDs physical stability is the API solubility in the carrier, because this value determines the maximal API load without a risk of phase separation and recrystallization. Phase-diagrams can be experimentally obtained by following the recrystallization of the API from a supersaturated homogeneous API-polymer solid solution, commonly produced by processes as solvent casting or comilling, which are very time-consuming (hours). The work deals with the construction of a temperature-composition EFV-Soluplus® phase diagram, from a thermal study of recrystallization of a supersaturated solid solution (85 wt% in EFV) generated by spray drying. This supersaturated solution is kept at a given annealing temperature to reach the equilibrium state and the amount that still remains dispersed in the polymer carrier at this equilibrium temperature is determined by means of the new glass transition temperature of the binary mixture. From our knowledge, this is the first study employing a fast process (spray drying) to prepare a supersaturated solid solution of an API in a polymer aiming to determine a temperature-composition phase diagram. The EFV solubility in Soluplus ranges from 20 wt% at 25 °C to 30 wt% at 40 °C. It can be a very useful preformulation tool for researchers studying amorphous solid dispersions of Efavirenz in Soluplus, to assist for predicting the stability of EFV-Soluplus ASDs at different EFV loadings and under different thermal conditions.

摘要

无定形固体分散体 (ASD) 被发现是克服活性药物成分 (API) 有限的水溶解度和差的口服生物利用度的一种成熟策略。影响 ASD 物理稳定性的主要参数之一是 API 在载体中的溶解度,因为该值决定了在没有相分离和重结晶风险的情况下可以加载的最大 API 量。相图可以通过从过饱和均相 API-聚合物固溶体中跟踪 API 的重结晶来实验获得,通常通过溶剂浇铸或共研磨等工艺来制备,这些工艺非常耗时(数小时)。这项工作涉及通过对通过喷雾干燥产生的过饱和固溶体(EFV 含量为 85wt%)的重结晶进行热研究,构建 EFV-Soluplus®的温度-组成相图。将该过饱和溶液保持在给定的退火温度下以达到平衡状态,并通过二元混合物的新玻璃化转变温度确定在该平衡温度下仍分散在聚合物载体中的量。据我们所知,这是首次使用快速工艺(喷雾干燥)来制备 API 在聚合物中的过饱和固溶体以确定温度-组成相图的研究。EFV 在 Soluplus 中的溶解度在 25°C 时为 20wt%,在 40°C 时为 30wt%。对于研究 Efavirenz 在 Soluplus 中的无定形固体分散体的研究人员来说,这可能是一个非常有用的预配方工具,可帮助预测在不同 EFV 载量和不同热条件下 EFV-Soluplus ASD 的稳定性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验